Xeris Biopharma Holdings, Inc.

XERS

US98422E1038

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.75 ^USD	+2.94%		+0.57%	-25.53%

Mar. 28	Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target	MT
Mar. 18	Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index	CI

Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Year 2024

January 04, 2024 at 07:00 am EST

Xeris Biopharma Holdings, Inc. provided revenue guidance for the year 2024. The company anticipates 2024 total revenue to grow from 2023 levels.

Latest news about Xeris Biopharma Holdings, Inc.

Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target	Mar. 28	MT
Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M	Mar. 06	MT
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024	Mar. 06	CI
Xeris Refinances its $150 Million Senior Secured Term Loan Facility with Hayfin Capital	Mar. 06	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Xeris Biopharma Holdings Seeks Acquisitions	Jan. 11	CI
Transcript : Xeris Biopharma Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	Jan. 11
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data	Jan. 10	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 10	MT
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen	Jan. 10	MT
Xeris Biopharma Shares Climb 12% on Amgen License Agreement	Jan. 10	DJ
Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment	Jan. 10	DJ
Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab	Jan. 10	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 04	MT
Sector Update: Health Care Stocks Gain Thursday Afternoon	Jan. 04	MT
Sector Update: Health Care	Jan. 04	MT
Xeris Biopharma Expects 2023 Revenue to be at High End of Previous Guidance; Shares Jump	Jan. 04	MT
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Year 2024	Jan. 04	CI
Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Year 2023	Jan. 04	CI
Transcript : Xeris Biopharma Holdings, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q3 Revenue $48.3M	Nov. 09	MT

Chart Xeris Biopharma Holdings, Inc.

Duration

Period

More charts

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patientsâ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushingâs syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Xeris Biopharma Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.75 USD

Average target price

4.75 USD

Spread / Average Target

+171.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
XERIS BIOPHARMA HOLDINGS, INC.	-25.53%	259M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals